Edition:
United States

Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

5.79USD
3:59pm EST
Change (% chg)

$-0.03 (-0.52%)
Prev Close
$5.82
Open
$5.85
Day's High
$5.98
Day's Low
$5.75
Volume
44,086
Avg. Vol
85,260
52-wk High
$6.65
52-wk Low
$1.34

Chart for

About

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low... (more)

Overall

Beta: --
Market Cap(Mil.): $260.70
Shares Outstanding(Mil.): 44.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 185.97 15.71
EPS (TTM): -- -- --
ROI: -- -11.84 31.93
ROE: -- -36.93 16.16

BRIEF-Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402

* PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402

Dec 07 2017

BRIEF-Pieris Pharmaceuticals appoints James Geraghty as chairman of board of directors

* Pieris Pharmaceuticals appoints James Geraghty as chairman of the board of directors

Nov 21 2017

BRIEF-Pieris Pharmaceuticals reports Q3 loss per share $0.16

* Pieris Pharmaceuticals reports financial results for the third quarter ended september 30, 2017, and provides corporate update

Nov 08 2017

BRIEF-Pieris Pharmaceuticals names Allan Reine CFO

* Pieris Pharmaceuticals appoints Allan Reine, M.D., as chief financial officer Source text for Eikon: Further company coverage:

Aug 10 2017

BRIEF-Sichuan Kelun Pharmaceutical unit signs license agreement with Pieris Pharmaceuticals

* Says its Sichuan-based unit signs license agreement with Pieris Pharmaceuticals Inc, regarding a patent of tumour immunotherapy

Aug 10 2017

BRIEF-Pieris Pharmaceuticals Q2 loss per share $0.23

* Pieris Pharmaceuticals reports financial results for the second quarter ended June 30, 2017 and provides corporate update

Aug 09 2017

BRIEF-Pieris Pharma announces results from 2017 annual meeting of stockholders

* Pieris Pharmaceuticals announces results from 2017 annual meeting of stockholders and provides update on therapeutic programs

Jul 05 2017

Earnings vs. Estimates